• New Drug

    Asked by gogolf on Thursday, August 1, 2013

    New Drug

    if anyone is taking Kadcyla (ado-trastuzumab emtsansine) I would love to hear from you. This is the new drug with Herceptin and a Chemo drug that works with it, I am not sure what side effects to watch for.

    3 Answers from the Community

    • Risa's Avatar
      Risa

      I have had my third treatment of Kadcyla and I have absolutely no side effects. No low blood counts, no constipation or diarreha. No headaches. I have a bit of insomnia but I think that is due to me getting used to going to bed earlier due to the fatigue I had from the prior treatments of chemo and radiation etc., so I tend to wake up in the early morning hours with insomnia.
      They say that Kadcyla is a miracle drug. Let's hope so. I will keep you posted as I proceed with my treatment. When are you going to start?

      almost 8 years ago
    • okimie's Avatar
      okimie

      I had my 1st treatment last Monday , Tuesday i got chills, bone pain, severe nausea, headaches and fatigue that lasted till Friday. I still have random bone pain and not much appetite. But blood counts were good this week :) Liver test on weds next week.

      about 7 years ago
    • rosevillemom's Avatar
      rosevillemom

      I started the TDM1 (Kadcyla) trial on Thursday. Would love to compare notes if your interested? I had small bit of nausea with first infusion (had port placed right before so meds from that I believe made me queasy). Also had iron infusion same day. Small upset stomach last night, better today. Feel like I worked out at the gym, kind of achy but don't need anything for it. Next infusion is July 3rd, I go every three weeks.

      about 7 years ago

    Help the community by answering this question:

    Create an account to post your answer Already have an account? Sign in!

    By using WhatNext, you agree to our User Agreement, and Privacy Policy


    Read and answer more breast cancer questions.  Also, don't forget to check out our Breast Cancer page.